Cost effectiveness of child pneumococcal conjugate vaccination in middle-income countries

International Health

Volumn 3, Issue 4, 2011, Pages 270-281

  Nakamura, Mari M ^a   Tasslimi, Azadeh ^b   Lieu, Tracy A ^a,c   Levine, Orin ^d   Knoll, Maria Deloria ^d   Russell, Louise B ^e   Sinha, Anushua ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c HARVARD PILGRIM HEALTH CARE   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e RUTGERS UNIVERSITY   (United States)

Author keywords

Cost effectiveness analysis; Decision analysis; Middle income countries; Seven valent pneumococcal conjugate vaccine; Ten valent pneumococcal conjugate vaccine; Thirteen valent pneumococcal conjugate vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; CHILD; COST EFFECTIVENESS ANALYSIS; DISABILITY ADJUSTED LIFE YEAR; DRUG COST; HERD IMMUNITY; HUMAN; INCOME; MAJOR CLINICAL STUDY; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SEROTYPE; VACCINATION;

EID: 84855981268     PISSN: 18763413     EISSN: 18763405     Source Type: Journal    
DOI: 10.1016/j.inhe.2011.08.004     Document Type: Article

References (25)

1. Klugman K., Cutts F., Adegbola R.A., Black S., Madhi S.A., O'Brien K.L., et al. Meta-analysis of the efficacy of conjugate vaccines against invasive pneumococcal disease. Pneumococcal vaccines: the impact of conjugate vaccine 2008, 317-326. ASM Press, Washington, DC. G.R. Siber, K. Klugman, P.H. Makela (Eds.).
2. WHO. WHO statistical information system (WHOSIS). Geneva: World Health Organization; 2008. [accessed 12 October 2007]. http://www.who.int/whosis/en/.
3. O'Brien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374:893-902.
4. Baraff L.J., Lee S.I., Schriger D.L. Outcomes of bacterial meningitis in children: a meta-analysis. Pediatr Infect Dis J 1993, 12:389-394.
5. Goetghebuer T., West T.E., Wermenbol V., Cadbury A.L., Milligan P., Lloyd-Evans N., et al. Outcome of meningitis caused by Streptococcus pneumoniae and Haemophilus influenzae type b in children in The Gambia. Trop Med Int Health 2000, 5:207-213.
6. Hausdorff W.P., Bryant J., Paradiso P.R., Siber G.R. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000, 30:100-121.
7. Constenla D, Gomez E, De La Hoz FP, O'Loughlin R, Sinha A, Valencia JE, et al. The burden of pneumococcal disease and the cost effectiveness of a pneumococcal vaccine in Latin America and the Caribbean: a review of the evidence and a preliminary economic analysis 2007. Washington, DC: Sabin Vaccine Institute; 2007. [accessed 1 August 2011]. http://new.paho.org/provac/index2.php%3Foption=com_docman%26task=doc_view%26gid=2240%26Itemid=99999999.
8. Hsu H.E., Shutt K., Moore M.R., Beall B., Bennett N.M., Craig A.S., et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009, 360:244-256.
9. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201:32-41.
10. Grijalva C.G., Nuorti J.P., Arbogast P.G., Martin S.W., Edwards K.M., Griffin M.R. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007, 369:1179-1186.
11. Moore M., Gertz R.E., Woodbury R.L., Barkocy-Gallagher G.A., Schaffner W., Lexau C., et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 2008, 197:1016-1027.
12. Constenla D. Evaluating the costs of pneumococcal disease in selected Latin American countries. Rev Panam Salud Publica 2007, 22:268-278.
13. Adam T., Evans D., Murray C.J. Econometric estimation of country-specific hospital costs. Cost Eff Resour Alloc 2003, 1:3.
14. Constenla D., Sinha A., Valencia J.E., Gomez E., de la Hoz F., Valenzuela M.T., et al. Identifying unit costs for use in regional economic evaluation: an illustrative analysis of childhood pneumococcal conjugate vaccine in Latin America and the Caribbean. Rev Panam Salud Publica 2009, 26:458-468.
15. Jack A. GSK in deal with Brazil for pneumococcal vaccine. Financial Times 27 September 2009.
16. International Labor Organization. Minimum wage database. Geneva: International Labor Organization; 2008. [accessed 3 July 2008]. http://www.ilo.org/travaildatabase/servlet/minimumwages.
17. Mulligan J, Fox-Rushby JA, Adam T, Johns B, Mills A. Unit costs of health care inputs in low and middle income regions. Washington DC: World Bank, Disease Control Priorities Project (DCPP) Working Paper No. 9, revised June 2005.
18. IDA Foundation. Price Indicator. August 2006. Amsterdam: IDA Foundation. [accessed 29 August 2011]. http://www.who.int/hiv/amds/Price%2520Indicator_IDA%2520Foundation%2520(August%25202006).pdf.
19. Management Sciences for Health International drug price indicator guide 2007, Management Sciences for Health, Boston, MA.
20. Drummond M.F., Sculpher M.J., Torrance B.J., Stoddart G.L. Methods for the economic evaluation of health care programmes 2005, Oxford University Press, New York, NY. 3rd ed.
21. Fox-Rushby J.A., Hanson K. Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy Plan 2001, 16:326-331.
22. Murray CJ, Lopez AD, editors. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. The Global Burden of Disease and Injury Series. Vol. 1. Boston, MA: Harvard University Press, for Harvard School of Public Health on behalf of the World Health Organization and The World Bank; 1996.
23. Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, et al., editors. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003. [accessed 2 August 2011]. http://www.who.int/choice/publications/p_2003_generalised_cea.pdf.
24. Sinha A., Levine O., Knoll M.D., Muhib F., Lieu T.A. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet 2007, 369:389-396.
25. Ray G.T., Whitney C.G., Fireman B.H., Ciuryla V., Black S.B. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J 2006, 25:494-501.